Human Molecular Genetics Advance Access originally published online on June 25, 2008
Human Molecular Genetics 2008 17(18):2863-2867; doi:10.1093/hmg/ddn183
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease
1 Inserm, U744, Institut Pasteur de Lille, Université de Lille 2, Lille, France 2 Inserm, U708, Hôpital de la Salpêtrière, Paris, France 3 Université Pierre et Marie Curie-Paris6, Paris, France 4 Eskitis Institue for Cell and Molecular Therapies, Griffith University, Queensland, Australia 5 EA2391, Department of Neurology, Memory Clinic, University Hospital of Lille, Lille, France 6 Inserm, U614, Faculty of Medicine, IFRMP, Rouen, France 7 Molecular Psychiatry Group, Queensland Institute of Medical Research, Brisbane, Australia
* To whom correspondence should be addressed at: unité INSERM 744, Institut Pasteur de Lille, BP 245, 1, rue du professeur Calmette, 59019 Lille cédex, France. Tel: +33 320 877391; Fax: +33 320 877894; Email: jean-charles.lambert{at}pasteur-lille.fr
Received May 26, 2008; Accepted June 22, 2008
Alzheimer's disease (AD) and Parkinson's disease (PD), the two most common neurodegenerative disorders in the elderly, have been hypothesized to share genetic determinants. Recently, Li et al. proposed that a variant in the NEDD9 gene may be one of these common genetic factors. We attempted to confirm this initial observation by conducting an equivalent analysis in terms of pathologies and sample size. We genotyped the NEDD9 rs760678 SNP in three independent AD case–control studies (n = 3176) and two independent PD case–control studies (n = 1855). However, we failed to detect an association of this SNP with the risk of developing AD or PD, in any of these populations. In conclusion, these data indicate that the rs760678 SNP of the NEDD9 gene is at best a weak genetic determinant of AD or PD.